# David Gruben

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/david-gruben/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,195 |
| Field | Rheumatoid Arthritis Research and Therapies |
| h-index | 33 |
| i10-index | 56 |
| Last Known Institution | Pfizer (United States) |
| OpenAlex ID | https://openalex.org/A5064863811 |
| ORCID iD | 0000-0003-3516-5289 |
| Works | 168 |

## Researcher papers

- [Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis](https://scholariq.org/papers/placebo-controlled-trial-of-tofacitinib-monotherapy-in-rheumatoid-arthritis/)
- [Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis](https://scholariq.org/papers/tofacitinib-or-adalimumab-versus-placebo-in-rheumatoid-arthritis/)
- [Tofacitinib versus Methotrexate in Rheumatoid Arthritis](https://scholariq.org/papers/tofacitinib-versus-methotrexate-in-rheumatoid-arthritis/)
- [Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial](https://scholariq.org/papers/tofacitinib-cp-690-550-in-combination-with-methotrexate-in-patients-with-active/)
- [Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study](https://scholariq.org/papers/tofacitinib-cp-690-550-in-patients-with-rheumatoid-arthritis-receiving/)
- [The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo](https://scholariq.org/papers/the-safety-and-efficacy-of-a-jak-inhibitor-in-patients-with-active-rheumatoid/)
- [Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis](https://scholariq.org/papers/tofacitinib-in-combination-with-nonbiologic-disease-modifying-antirheumatic/)
- [Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs](https://scholariq.org/papers/phase-iib-dose-ranging-study-of-the-oral-jak-inhibitor-tofacitinib-cp-690-550-or/)
- [A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone](https://scholariq.org/papers/a-phase-iib-dose-ranging-study-of-the-oral-jak-inhibitor-tofacitinib-cp-690-550/)
- [Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies](https://scholariq.org/papers/safety-and-efficacy-of-tofacitinib-an-oral-janus-kinase-inhibitor-for-the/)
- [The Economic and Psychosocial Comorbidity Burden Among Adults with Moderate-to-Severe Atopic Dermatitis in Europe: Analysis of a Cross-Sectional Survey](https://scholariq.org/papers/the-economic-and-psychosocial-comorbidity-burden-among-adults-with-moderate-to/)
- [Clinical and Humanistic Burden of Atopic Dermatitis in Europe: Analyses of the National Health and Wellness Survey](https://scholariq.org/papers/clinical-and-humanistic-burden-of-atopic-dermatitis-in-europe-analyses-of-the/)

## Researcher topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)

## Researcher university

- [Pfizer (United States)](https://scholariq.org/institutions/pfizer-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.